Begins Coverage on VolitionRx (NYSE:VNRX)

Research analysts at started coverage on shares of VolitionRx (NYSE:VNRXGet Rating) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

VolitionRx Stock Down 11.0 %

Shares of VolitionRx stock opened at $2.03 on Friday. VolitionRx has a 12-month low of $1.91 and a 12-month high of $4.14. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $109.19 million, a price-to-earnings ratio of -3.90 and a beta of 1.70. The stock’s fifty day moving average is $2.23.

VolitionRx (NYSE:VNRXGet Rating) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.18). VolitionRx had a negative net margin of 15,827.93% and a negative return on equity of 148.44%. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $10.01 million. Analysts expect that VolitionRx will post -0.51 EPS for the current year.

VolitionRx Company Profile

(Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

Further Reading

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with's FREE daily email newsletter.